139 related articles for article (PubMed ID: 35001343)
1. Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study.
Mathews L; Ding N; Sang Y; Loehr LR; Shin JI; Punjabi NM; Bertoni AG; Crews DC; Rosamond WD; Coresh J; Ndumele CE; Matsushita K; Chang PP
J Racial Ethn Health Disparities; 2023 Feb; 10(1):118-129. PubMed ID: 35001343
[TBL] [Abstract][Full Text] [Related]
2. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
[TBL] [Abstract][Full Text] [Related]
3. Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes.
Palin V; Drozd M; Garland E; Malik A; Straw S; McGinlay M; Simms A; Gatenby VK; Sengupta A; Levelt E; Witte KK; Kearney MT; Cubbon RM
ESC Heart Fail; 2022 Oct; 9(5):3298-3307. PubMed ID: 35796239
[TBL] [Abstract][Full Text] [Related]
4. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
[TBL] [Abstract][Full Text] [Related]
5. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
[TBL] [Abstract][Full Text] [Related]
6. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
[TBL] [Abstract][Full Text] [Related]
7. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
8. Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction.
Chen X; Cui X; Thunström E; Pivodic A; Dahlström U; Fu M
Clin Res Cardiol; 2021 Jul; 110(7):1051-1062. PubMed ID: 33394127
[TBL] [Abstract][Full Text] [Related]
9. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).
Patil T; Ali S; Kaur A; Akridge M; Eppes D; Paarlberg J; Parashar A; Jarmukli N
J Cardiovasc Transl Res; 2022 Dec; 15(6):1424-1435. PubMed ID: 35501544
[TBL] [Abstract][Full Text] [Related]
12. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
15. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
16. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
17. Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
Cutshall BT; Duhart BT; Saikumar J; Samarin M; Hutchison L; Hudson JQ
Am J Med Sci; 2018 Mar; 355(3):247-251. PubMed ID: 29549927
[TBL] [Abstract][Full Text] [Related]
18. Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
Sumarsono A; Xie L; Keshvani N; Zhang C; Patel L; Alonso WW; Thibodeau JT; Fonarow GC; Van Spall HGC; Messiah SE; Pandey A
Circulation; 2024 Feb; 149(7):510-520. PubMed ID: 38258605
[TBL] [Abstract][Full Text] [Related]
19. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
20. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
Bitar S; Thilly N; Agrinier N
Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
